RU2019138175A3 - - Google Patents

Download PDF

Info

Publication number
RU2019138175A3
RU2019138175A3 RU2019138175A RU2019138175A RU2019138175A3 RU 2019138175 A3 RU2019138175 A3 RU 2019138175A3 RU 2019138175 A RU2019138175 A RU 2019138175A RU 2019138175 A RU2019138175 A RU 2019138175A RU 2019138175 A3 RU2019138175 A3 RU 2019138175A3
Authority
RU
Russia
Application number
RU2019138175A
Other versions
RU2019138175A (ru
RU2768473C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019138175A publication Critical patent/RU2019138175A/ru
Publication of RU2019138175A3 publication Critical patent/RU2019138175A3/ru
Application granted granted Critical
Publication of RU2768473C2 publication Critical patent/RU2768473C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2019138175A 2017-04-27 2018-04-26 Гетероциклическое соединение RU2768473C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017-087959 2017-04-27
JP2017087959 2017-04-27
PCT/JP2018/016995 WO2018199235A1 (ja) 2017-04-27 2018-04-26 複素環化合物

Publications (3)

Publication Number Publication Date
RU2019138175A RU2019138175A (ru) 2021-05-27
RU2019138175A3 true RU2019138175A3 (ru) 2021-06-10
RU2768473C2 RU2768473C2 (ru) 2022-03-24

Family

ID=63919858

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019138175A RU2768473C2 (ru) 2017-04-27 2018-04-26 Гетероциклическое соединение

Country Status (14)

Country Link
US (1) US10919891B2 (ru)
EP (1) EP3617209A4 (ru)
JP (1) JP7177042B2 (ru)
CN (1) CN110573512B (ru)
AU (1) AU2018257331B2 (ru)
BR (1) BR112019022465A2 (ru)
CA (1) CA3061600A1 (ru)
CO (1) CO2019012270A2 (ru)
IL (1) IL270155B (ru)
MX (1) MX2019012808A (ru)
RU (1) RU2768473C2 (ru)
SG (1) SG11201909812VA (ru)
WO (1) WO2018199235A1 (ru)
ZA (1) ZA201907792B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020266566A1 (en) * 2019-05-01 2021-11-11 Boehringer Ingelheim International Gmbh Solid forms of a GlyT1 inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2003129060A (ru) * 2001-03-14 2005-04-10 Грюненталь ГмбХ (DE) Замещенные пиразоло-и тиазолопиримидины
CN1771231B (zh) 2002-08-26 2011-05-25 武田药品工业株式会社 钙受体调节性化合物及其用途
KR101050700B1 (ko) * 2002-08-26 2011-07-20 다케다 야쿠힌 고교 가부시키가이샤 칼슘 수용체 조절 화합물 및 이의 용도
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7501405B2 (en) * 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
JP2005239611A (ja) 2004-02-25 2005-09-08 Takeda Chem Ind Ltd ピラゾロピリミジン誘導体およびその用途
US20090304821A1 (en) 2006-03-08 2009-12-10 Takeda Pharmaceutical Company Limited Pharmaceutical Combination
CA2860933C (en) 2012-02-03 2020-01-14 Sanofi Fused pyrroledicarboxamides and their use as pharmaceuticals
JP6249952B2 (ja) 2012-10-16 2017-12-20 武田薬品工業株式会社 複素環化合物
CN104910118B (zh) 2014-03-13 2017-07-04 中国科学院上海药物研究所 一类双香豆素类化合物及其制备方法和用途
WO2017110881A1 (ja) 2015-12-25 2017-06-29 武田薬品工業株式会社 医薬
EP3437644B1 (en) 2016-03-28 2021-06-30 Takeda Pharmaceutical Company Limited Compounds for use in the treatment of pulmonary hypertension

Also Published As

Publication number Publication date
IL270155B (en) 2022-07-01
AU2018257331B2 (en) 2022-04-07
CN110573512B (zh) 2022-09-06
IL270155A (ru) 2019-12-31
AU2018257331A1 (en) 2019-11-14
SG11201909812VA (en) 2019-11-28
EP3617209A1 (en) 2020-03-04
ZA201907792B (en) 2022-03-30
JP7177042B2 (ja) 2022-11-22
US10919891B2 (en) 2021-02-16
CN110573512A (zh) 2019-12-13
RU2019138175A (ru) 2021-05-27
EP3617209A4 (en) 2020-08-26
MX2019012808A (es) 2022-02-21
CA3061600A1 (en) 2019-10-25
US20200131174A1 (en) 2020-04-30
CO2019012270A2 (es) 2020-02-28
JPWO2018199235A1 (ja) 2020-03-12
BR112019022465A2 (pt) 2020-05-12
WO2018199235A1 (ja) 2018-11-01
RU2768473C2 (ru) 2022-03-24

Similar Documents

Publication Publication Date Title
RU2019138175A3 (ru)
BR202018014992U2 (ru)
BR202017025154U2 (ru)
BR202017021228U2 (ru)
BR202017020981U2 (ru)
BE2017C035I2 (ru)
BR202017017068U2 (ru)
BR202017016984U2 (ru)
BR202017016924U2 (ru)
BR202017012548U2 (ru)
BR202017011220U2 (ru)
BR202017010814U2 (ru)
BR202017010373U2 (ru)
BR202017009870U2 (ru)
BR202017006953U2 (ru)
BR202017004898U2 (ru)
BR202017002937U2 (ru)
BR202017002826U2 (ru)
CN304001106S (ru)
CN303992506S (ru)
CN303991336S (ru)
CN303991096S (ru)
CN303990998S (ru)
CN303990988S (ru)
CN303952054S8 (ru)